March 25, 2021
Managing Intellectual Property
Managing Intellectual Property analyzed ANDA litigation data from Docket Navigator, which highlights the District of New Jersey and the District of Delaware as the top venues for ANDA litigation in 2020. It is not surprising these are the top venues, as the majority of generics companies in the United States are based or incorporated in Delaware or New Jersey. Managing Intellectual Property interviewed Finnegan partner Laura Masurovsky for her thoughts on the data and the future of the ANDA litigation landscape.
Laura said, “My suspicion is that because of the expertise of these courts in pharma patent cases, there will be just as many if not more cases filed in Delaware and New Jersey in the future.”
Read “How 2020 ANDA Litigation Played Out – and What to Expect for 2021”
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.